EN · OpenOnco · DIS-CHOLANGIOCARCINOMA — Auto-stub (75% наповненість)
← Back to galleryFeedback on this caseUA
OpenOnco · Treatment Plan
Treatment plan — DIS-CHOLANGIOCARCINOMA
PLAN-AUTO-CHOLANGIOCARCINOMA-001-V1 · v1 · 2026-04-27
Patient
AUTO-CHOLANGIOCARCINOMA-001 · Algorithm: ALGO-CHOLANGIO-1L

Clinical significance of mutations (ESCAT / OncoKB)

Tumor-board context — the engine does not use these tiers to rank tracks
BiomarkerVariantESCATOncoKBClinical significanceDrugsSources
No clinically actionable variants matched in this profile.

Treatment options (1 tracks)

Standard plan
★ DEFAULT
Indication
IND-CHOLANGIO-ADVANCED-GEM-CIS
Regimen
Gemcitabine + cisplatin (advanced biliary tract cancer, 1L — ABC-02)
Drugs + NSZU
  • Gemcitabine (DRUG-GEMCITABINE) Gemcitabine 1000 mg/m² · Per regimen schedule · IV ⚠ NSZU — not for this indication
  • Cisplatin (DRUG-CISPLATIN) cisplatin 25 mg/m² IV d1, d8 q3w × 8 cycles · Per regimen schedule · IV ⚠ NSZU — not for this indication
Reason
Engine default per algorithm ALGO-CHOLANGIO-1L: {'step': None, 'note': 'decision tree fell through; using default_indication', 'result': 'IND-CHOLANGIO-ADVANCED-GEM-CIS', 'fired_red_flags': []}

Timeline

Treatment timeline — derived from regimen + monitoring schedule

Standard plan

Induction · Gemcitabine + cisplatin (advan
21-day cycles × 6 cycles or until progression / toxicity

MDT brief

Data quality

  • Unevaluated RedFlags: RF-CHOLANGIOCARCINOMA-FRAILTY-AGE, RF-CHOLANGIOCARCINOMA-HIGH-RISK-BIOLOGY, RF-CHOLANGIOCARCINOMA-INFECTION-SCREENING, RF-CHOLANGIOCARCINOMA-ORGAN-DYSFUNCTION, RF-CHOLANGIOCARCINOMA-TRANSFORMATION-PROGRESSION

Skill catalog (0/16 activated in this plan)

All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).
Specialistskill_idVersionLast reviewedSign-offsDomain
Specialist з клітинної терапії (CAR-T)cellular_therapy_specialistv0.1.02026-04-250cellular_therapy
Клінічний фармацевтclinical_pharmacistv0.1.02026-04-250clinical_pharmacy
Гематолог / онкогематологhematologistv0.1.02026-04-250hematology_oncology
Гематопатолог (специфічно для лімфом / лейкозів / мієломи)hematopathologistv0.1.02026-04-250hematopathology
Інфекціоніст / гепатологinfectious_disease_hepatologyv0.1.02026-04-250infectious_diseases
Медичний онколог (хіміотерапевт солідних пухлин)medical_oncologistv0.1.02026-04-250solid_oncology
Молекулярний генетик / молекулярний онкологmolecular_geneticistv0.1.02026-04-250molecular_oncology
Паліативна допомогаpalliative_carev0.1.02026-04-250palliative_care
Патолог (загальний)pathologistv0.1.02026-04-250pathology
Сімейний лікар / терапевтprimary_carev0.1.02026-04-250primary_care
Психолог / онкопсихологpsychologistv0.1.02026-04-250psychosocial
Радіотерапевт (променева терапія)radiation_oncologistv0.1.02026-04-250radiation_oncology
Лікар-радіологradiologistv0.1.02026-04-250diagnostic_imaging
Соціальний працівник / кейс-менеджерsocial_worker_case_managerv0.1.02026-04-250psychosocial
Хірург-онкологsurgical_oncologistv0.1.02026-04-250surgical_oncology
Specialist з трансплантації (BMT)transplant_specialistv0.1.02026-04-250cellular_therapy

Sources cited

Експериментальні опції (клінічні дослідження)

Третій трек плану — open-enrollment trials з ClinicalTrials.gov. Останнє оновлення: 2026-04-27. Render-time metadata; engine selection не змінюється цим блоком (CHARTER §8.3).
NCTNamePhaseСтатусСпонсорUAВключення (фрагмент)
NCT06028724A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)N/ARECRUITINGCentro di Riferimento Oncologico - Aviano—
NCT07486713Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesPHASE4RECRUITINGRigel Pharmaceuticals—
NCT06270706A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsPHASE1RECRUITINGPliant Therapeutics, Inc.—
NCT06493734Stereotactic Body Radiation Therapy After Chemotherapy for Unresectable Perihilar CholangiocarcinomaNARECRUITINGErasmus Medical Center—
NCT03823144Intravital Microscopy in Human Solid TumorsNARECRUITINGMayo Clinic—
NCT02012699Integrated Cancer Repository for Cancer ResearchN/ARECRUITINGUniversity of Nebraska—
NCT04318834Molecular Profiling of Advanced Biliary Tract CancersNARECRUITINGMcGill University Health Centre/Research Institute of the McGill University Health Centre—
NCT06168292Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic CholangiocarcinomaNARECRUITINGNational Cancer Center, Korea—
NCT07260175Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaPHASE2RECRUITINGInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest—
NCT06048133Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)PHASE2RECRUITINGNataliya Uboha—

Перевіряти статус набору безпосередньо у дослідницькому центрі. Дані ctgov можуть відставати від поточного статусу UA-сайтів.

Доступність опцій в Україні

Per-track UA registration · НСЗУ · cost · access pathway. Render-time metadata; engine selection не залежить від цих полів (CHARTER §8.3).
ОпціяРеєстрація UAНСЗУCost orientationAccess pathway
Standard plan
Gemcitabine + cisplatin (advanced biliary tract cancer, 1L — ABC-02) (REG-GEMCITABINE-CISPLATIN-CHOLANGIO)
✓ зареєстровано✓ покривається₴-? — verify pathwayНСЗУ formulary
Trial · NCT06028724
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT07486713
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT06270706
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT06493734
Stereotactic Body Radiation Therapy After Chemotherapy for Unresectable Perihilar Cholangiocarcinoma
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT03823144
Intravital Microscopy in Human Solid Tumors
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT02012699
Integrated Cancer Repository for Cancer Research
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT04318834
Molecular Profiling of Advanced Biliary Tract Cancers
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT06168292
Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT07260175
Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT06048133
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor

Інформація про ціни — orientation. Перевіряти у конкретній аптеці / foundation / трайл-сайті. Status updated: 2026-04-27.

plan_id: PLAN-AUTO-CHOLANGIOCARCINOMA-001-V1 | version: 1 | generated: 2026-04-27T12:36:01.399502+00:00
Per FDA non-device CDS positioning (CHARTER §15): Outpatient oncology treatment planning to support tumor-board discussion. Not a medical device; not for autonomous clinical decision-making.
Per FDA non-device CDS positioning (CHARTER §15): Both treatment options below are presented for review. The engine's selection of a 'recommended' default does not constitute a clinical decision. Final treatment selection requires HCP judgment incorporating information not available to the system.
This document is an informational resource supporting tumor-board discussion (per CHARTER §11). It is not a system that makes clinical decisions. Every recommendation must be verified by the treating physician.